189 related articles for article (PubMed ID: 31918425)
1. Does the Timing of Surgery after Neoadjuvant Therapy in Breast Cancer Patients Affect the Outcome?
Suleman K; Almalik O; Haque E; Mushtaq A; Badran A; Alsayed A; Ajarim D; Al-Tweigeri T; Jastaniyah N; Elhassan T; Alkhayal W
Oncology; 2020; 98(3):168-173. PubMed ID: 31918425
[TBL] [Abstract][Full Text] [Related]
2. Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients.
Sanford RA; Lei X; Barcenas CH; Mittendorf EA; Caudle AS; Valero V; Tripathy D; Giordano SH; Chavez-MacGregor M
Ann Surg Oncol; 2016 May; 23(5):1515-21. PubMed ID: 26678405
[TBL] [Abstract][Full Text] [Related]
3. Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes.
Liu Y; Zhang KC; Huang XH; Xi HQ; Gao YH; Liang WQ; Wang XX; Chen L
World J Gastroenterol; 2018 Jan; 24(2):257-265. PubMed ID: 29375211
[TBL] [Abstract][Full Text] [Related]
4. [The role of postmastectomy radiotherapy in clinical T1-3N1M0 breast cancer patients with pathological negative lymph nodes after neoadjuvant chemotherapy and mastectomy].
Rong QL; Wang SL; Tang Y; Jin J; Song YW; Wang WH; Liu YP; Fang H; Ren H; Liu XF; Yu ZH; Li YX
Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):445-452. PubMed ID: 28635235
[No Abstract] [Full Text] [Related]
5. Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients.
Goorts B; van Nijnatten TJ; de Munck L; Moossdorff M; Heuts EM; de Boer M; Lobbes MB; Smidt ML
Breast Cancer Res Treat; 2017 May; 163(1):83-91. PubMed ID: 28205044
[TBL] [Abstract][Full Text] [Related]
6. Impact of wait time from neoadjuvant chemotherapy to surgery in breast cancer: Does time to surgery affect patient outcomes? : Time from Neoadjuvant Chemotherapy to Surgery.
Lai V; Hajjaj O; Le D; Shokoohi A; Chia S; Simmons C
Breast Cancer Res Treat; 2020 Dec; 184(3):755-762. PubMed ID: 33001336
[TBL] [Abstract][Full Text] [Related]
7. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
8. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Campbell JI; Yau C; Krass P; Moore D; Carey LA; Au A; Chhieng D; Giri D; Livasy C; Mies C; Rabban J; Sarode VR; Singh B; Esserman L; Chen YY
Breast Cancer Res Treat; 2017 Aug; 165(1):181-191. PubMed ID: 28577078
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of survival in pathologic incomplete response patients with locally advanced breast cancer after neoadjuvant chemotherapy.
Huang O; Jiang M; Chen XS; Wu JY; Chen WG; Li YF; Shen KW
Cell Biochem Biophys; 2015 Mar; 71(2):1181-90. PubMed ID: 25427887
[TBL] [Abstract][Full Text] [Related]
10. Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy.
Ataseven B; Lederer B; Blohmer JU; Denkert C; Gerber B; Heil J; Kühn T; Kümmel S; Rezai M; Loibl S; von Minckwitz G
Ann Surg Oncol; 2015 Apr; 22(4):1118-27. PubMed ID: 25297900
[TBL] [Abstract][Full Text] [Related]
11. Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy: A Review of the Evidence.
Chapman CH; Jagsi R
Oncology (Williston Park); 2015 Sep; 29(9):657-66. PubMed ID: 26384802
[TBL] [Abstract][Full Text] [Related]
12. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05).
Shim SJ; Park W; Huh SJ; Choi DH; Shin KH; Lee NK; Suh CO; Keum KC; Kim YB; Ahn SD; Kim SS; Ha SW; Chie EK; Kim K; Shin HS; Kim JH; Lee HS
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):65-72. PubMed ID: 24161425
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy in stage III breast cancer.
Alassas M; Chu Q; Burton G; Ampil F; Mizell J; Li BD
Am Surg; 2005 Jun; 71(6):487-92. PubMed ID: 16044927
[TBL] [Abstract][Full Text] [Related]
14. From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing?
Chen Q; Mao R; Zhao J; Bi X; Li Z; Huang Z; Zhang Y; Zhou J; Zhao H; Cai J
Cancer Med; 2020 Nov; 9(21):7849-7862. PubMed ID: 32886456
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer.
Silva SB; Pereira AAL; Marta GN; de Barros Lima KML; de Freitas TB; Matutino ARB; de Azevedo Souza MCL; de Azevedo RGMV; de Viveiros PAH; da Silva Lima JM; Filassi JR; de Andrade Carvalho H; Piato JRM; Mano MS
Breast; 2018 Apr; 38():39-44. PubMed ID: 29223797
[TBL] [Abstract][Full Text] [Related]
16. The impact of age group in breast cancer survival outcome according to neoadjuvant treatment response: A matched case-control study.
Li CL; Wu CC; Kan JY; Chen FM; Hou MF; Chuang CH; Huang HI; Ou-Yang F
Kaohsiung J Med Sci; 2022 Mar; 38(3):277-282. PubMed ID: 34825475
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
Gamucci T; Pizzuti L; Sperduti I; Mentuccia L; Vaccaro A; Moscetti L; Marchetti P; Carbognin L; Michelotti A; Iezzi L; Cassano A; Grassadonia A; Astone A; Botticelli A; Magnolfi E; Di Lauro L; Sergi D; Fuso P; Tinari N; Barba M; Maugeri-Saccà M; Landucci E; Conti F; Sanguineti G; De Tursi M; Iafrate G; Giordano A; Ciliberto G; Natoli C; Vici P
J Cell Physiol; 2018 Mar; 233(3):2313-2323. PubMed ID: 28710865
[TBL] [Abstract][Full Text] [Related]
18. Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
de Groot S; Pijl H; Charehbili A; van de Ven S; Smit VTHBM; Meershoek-Klein Kranenbarg E; Heijns JB; van Warmerdam LJC; Kessels LW; Dercksen MW; Pepels MJAE; van Laarhoven HWM; Vriens BEPJ; Putter H; Fiocco M; Liefers GJ; van der Hoeven JJM; Nortier JWR; Kroep JR;
Breast Cancer Res; 2019 Aug; 21(1):97. PubMed ID: 31455425
[TBL] [Abstract][Full Text] [Related]
19. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
[TBL] [Abstract][Full Text] [Related]
20. Optimal timing of surgery following breast cancer neoadjuvant chemotherapy: A systematic review and meta-analysis.
Cullinane C; Shrestha A; Al Maksoud A; Rothwell J; Evoy D; Geraghty J; McCartan D; McDermott EW; Prichard RS
Eur J Surg Oncol; 2021 Jul; 47(7):1507-1513. PubMed ID: 33589241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
